Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment;Association gemcitabine et docetaxel dans le traitement des sarcomes des tissus mous

Bulletin du Cancer

Volumn 94, Issue SPEC. ISS., 2007, Pages

  Bay, Jacques Olivier ^a   Cabrespine, Aurélie ^a   Gilliot, Olivier ^a   Bailly, Corine ^a   Vincent, Catherine ^a   Mishellany, Florence ^a   Gimbergues, Pierre ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

Docetaxel; Gemcitabine; Soft tissue sarcomas

Indexed keywords

DOCETAXEL; GEMCITABINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; LEIOMYOSARCOMA; MONOTHERAPY; REVIEW; SOFT TISSUE SARCOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DEOXYCYTIDINE; HUMANS; SARCOMA; TAXOIDS;

EID: 34547784589     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0247     Document Type: Review

References (37)

1. Stoeckle E, Kantor G, Thomas L, Coindre JM, Bui BN. {Surgery of recurrent soft tissue sarcoma of the extremities and the trunkwall : a comparison to primary sarcoma}. Bull Cancer 2004 ; 91 : 853-60.
2. Bonvalot S. {Soft tissue sarcoma : improved quality of life with new surgical approaches}. Bull Cancer 2002 ; 89 : 1045-52.
3. Fayette J, Blay JY. {Adjuvant chemotherapy in the treatment of sarcomas}. Bull Cancer 2006 ; 93 : 257-61.
4. Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM, Brennan MF. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 1999 ; 85 : 389-95.
5. Bui BN, Tabrizi R, Dagada C, Trufflandier N, St ckle E, Coindre JM. {Update on soft tissue sarcomas}. Bull Cancer 2002 ; 89 : 100-7.
6. O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, Grumet GN, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977 ; 39 : 1940-8.
7. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989 ; 7 : 1208-16.
8. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna : 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989 ; 7 : 126-31.
9. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am 1995 ; 9 : 765-85.
10. Santoto A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas : a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995 ; 13 : 1537-45.
11. Gottlieb JA, Benjamin RS, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 1976 ; 60 : 199-203.
12. Quirt I, Eisenhauer E, Bramwell V, Knowling M, Grafton C, Hirte W, et al. Phase II study of mitoxantrone in untreated and previously minimally treated patients with metastatic soft tissue sarcomas. Cancer Treat Rep 1987 ; 71 : 1109-10.
13. Goldstein D, Cheuvart B, Trump DL, Shiraki M, Comis RL, Tormey DC, et al. Phase II trial of carboplatin in soft-tissue sarcoma. Am J Clin Oncol 1990 ; 13 : 420-3.
14. Bramwell VH, Eisenhauer EA, Blackstein M, Boos G, Knowling M, Jolivet J, et al. Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 1995 ; 6 : 847-9.
15. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am 1995 ; 9 : 765-85.
16. Palumbo R, Palmeri S, Antimi M, Gatti C, Raffo P, Villani G, et al. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol 1997 ; 8 : 1159-62.
17. Pivot X, Chevreau C, Cupissol D, Lortholary A, Bui NB, Eymard JC, et al. Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma. Am J Clin Oncol 2002 ; 25 : 561-4.
18. Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Meazza C, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas : pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 2004 ; 101 : 1664-71.
19. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004 ; 22 : 1480-90.
20. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2′, 2′-difluorodeoxycytidine 5-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991 ; 27 : 258-62.
21. Hensley ML, Maki R, Venkattaman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma : results of a phase II trial. J Clin Oncol 2002 ; 20 : 2824-31.
22. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 1995 ; 22(Suppl 11) : 42-6.
23. Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy : a phase II study. Cancer Chemother Pharmacol 2000 ; 45 : 177-81.
24. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001 ; 19 : 3483-9.
25. Svancarova L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002 ; 38 : 556-9.
26. Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002 ; 94 : 3225-9.
27. Okuno S, Ryan LM, Edmonson JH, Priebat DA, Blum RH. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797) : a trial of the Eastern Cooperative Oncology Group. Cancer 2003 ; 97 : 1969-73.
28. Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 2000 ; 11 : 325-9.
29. Look KY, Sandler A, Blessing JA, Lucci 3rd JA, Rose PG. Gynecologic Oncology Group (GOG) Study. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma : a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 2004 ; 92 : 644-7.
30. Von Burton G, Rankin C, Zalupski MM, Mills GM, Borden EC, Karen A. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol 2006 ; 29 : 59-61.
31. Kostler WJ, Brodowicz T, Attems Y, Hejna M, Tomek S, Amann G, et al. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma : results of a phase II trial. Ann Oncol 2001 ; 12 : 1281-8.
32. van Hoesel QG, Verweij J, Catimel G, Clavel M, Kerbrat P, van Oosterom AT, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1994 ; 5 : 539-42.
33. Edmonson JH, Ebbert LP, Nascimento AG, Jung SH, McGaw H, Gerstner JB. Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol 1996 ; 19 : 574-6.
34. Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults : a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000 ; 18 : 2081-6.
35. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004 ; 22 : 1706-12.
36. Hensley ML, Anderson S, Soslow R. Activity of gemcitabine plus docetaxel in leiomyosarcoma (LMS) and other histologies : report of an expanded phase II trial (ASCO 04). J Clin Oncol 2004 : 23 (abstt. 9010).
37. Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas : a retrospective analysis. Int J Cancer 2006 ; 119 : 706-11.